Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

A phase I study of cabozantinib (XL184) in patients with renal cell cancer.

A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Ann Oncol. 2014 Aug; 25(8):1603-8.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.